Creyon Bio engineers RNA-based medicines and oligonucleotide-based medicines (OBMs) aiming for predictable safety and efficacy profiles. It builds proprietary, purpose-built datasets that inform machine learning models to rapidly identify design rules and engineering principles for safe and effective OBMs. The company raised $40M in Seed and Series A financing and intends to use the funds to continue optimization of its platform and expand the team. Leadership includes Co-founder, CEO and President Chris Hart and Co-founder and Chief Scientific Officer Swagatam Mukhopadhyay, Ph.D.; senior team members include Nathan Billings, Ph.D., Chief Strategy Officer, and Monica McArthur, Ph.D., Chief Technology Officer. Its board features Kiersten Stead (DCVC Bio), Zavain Dar (Lux Capital) and independent member Dennis Langer, M.D., J.D. Creyon operates from San Diego, CA and Research Triangle Park, NC and combines chemists, biologists, and computational scientists to tackle the drug design problem from multiple angles.

Total raised

$40M

Funding rounds

2

Latest round

Seed

Latest activity

Mar 2022